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PURPOSE. To describe the cumulative 6-year incidence of visual impairment (VI) and blindness
in an adult Kenyan population. The Nakuru Posterior Segment Eye Disease Study is a
population-based sample of 4414 participants aged ‡50 years, enrolled in 2007–2008. Of
these, 2170 (50%) were reexamined in 2013–2014.
METHODS. The World Health Organization (WHO) and US definitions were used to calculate
presenting visual acuity classifications based on logMAR visual acuity tests at baseline and
follow-up. Detailed ophthalmic and anthropometric examinations as well as a questionnaire,
which included past medical and ophthalmic history, were used to assess risk factors for study
participation and vision loss. Cumulative incidence of VI and blindness, and factors associated
with these outcomes, were estimated. Inverse probability weighting was used to adjust for
nonparticipation.
RESULTS. Visual acuity measurements were available for 2164 (99.7%) participants. Using WHO
definitions, the 6-year cumulative incidence of VI was 11.9% (95%CI [confidence interval]:
10.3–13.8%) and blindness was 1.51% (95%CI: 1.0–2.2%); using the US classification, the
cumulative incidence of blindness was 2.70% (95%CI: 1.8–3.2%). Incidence of VI increased
strongly with older age, and independently with being diabetic. There are an estimated 21
new cases of VI per year in people aged ‡50 years per 1000 people, of whom 3 are blind.
Therefore in Kenya we estimate that there are 92,000 new cases of VI in people aged ‡50
years per year, of whom 11,600 are blind, out of a total population of approximately 4.3
million people aged 50 and above.
CONCLUSIONS. The incidence of VI and blindness in this older Kenyan population was
considerably higher than in comparable studies worldwide. A continued effort to strengthen
the eye health system is necessary to support the growing unmet need in an aging and
growing population.
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Global estimates based on recent population-based surveyssuggest that approximately 191 to 285 million people live
with visual impairment (VI; defined as visual acuity of <6/18 or
<20/60 in the better eye), of whom 32 to 39 million people are
bilaterally blind (visual acuity < 3/60 or < 20/400 in the better
eye).1,2 Overall, VI is ranked sixth in the global burden of
disease in terms of disability-adjusted life-years (DALYs)3 and is
associated with increased mortality.4,5 Despite a reduction in
the prevalence of blindness in sub-Saharan Africa over the last
two decades, the numbers with VI have risen due to an increase
in population and longevity,6 though data are sparse.
Longitudinal studies provide the opportunity to investigate
the natural history of disease, which is essential to plan health
services. However, despite a large body of data globally on the
prevalence and causes of eye disease, data on incident visual
loss from population-based cohorts are limited, due to
prohibitive costs and complex logistical and planning challeng-
es. Consequently, to date, no longitudinal, population-based
studies of eye disease have been undertaken in sub-Saharan
Africa, and there have been only a small number worldwide,
predominantly in high-income settings.7–10 Inferring data from
high-income cohorts is not appropriate for low-income settings,
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and data are required from low-income countries for effective
planning of eye care services.
The aim of this study was to estimate the 6-year incidence
and risk factors for incident VI and blindness (both bilateral
and unilateral) in a cohort of adult Kenyans.
MATERIALS AND METHODS
The methodology of the Nakuru Eye Disease Cohort Study has
been reported in detail previously11 and is summarized here.
Ethical Approval
The study adhered to the tenets of the Declaration of Helsinki
and was approved by the Ethics Committee of London School
of Hygiene and Tropical Medicine at both baseline and follow-
up (LSHTM Ref. 6192). Baseline approval was provided by the
Kenya Medical Research Institute Ethics Committee and by the
African Medical and Research Foundation (AMREF) Ethics
Committee, Kenya, for the follow-up (AMREF-ESRC P44/12).
For both phases, approval was granted by the Rift Valley
Provincial Medical Officer and the Nakuru District Medical
Officer of Health. Approval was sought from the administrative
heads in each cluster. Informed written (or thumbprint)
consent was obtained from all participants after the objectives
of the survey and the examination process were explained to
those eligible in the local dialect, in the presence of a witness.
Participants identified with eye conditions, or other health
conditions, were referred to local services.
Baseline Study Population
The baseline population-based survey was conducted in 2007–
2008. The sample size of 5000 participants aged ‡50 years was
calculated based on an expected prevalence of visual acuity
(VA) < 20/40 in the better eye due to posterior segment eye
diseases (PSED, the primary outcome for the baseline survey)
of 3.0% in this age group, precision of 0.5%, design effect of
1.5, and a response rate of 90%.
A total of 100 clusters each of 50 participants were selected
with a probability proportional to the size of the population
across Nakuru district. Households were selected within
clusters using a modified compact segment sampling meth-
od.12 An eligible individual was defined as someone aged ‡50
years living in the household for at least 3 months in the
previous year. All participants were invited to undergo a
comprehensive ophthalmic examination at a screening clinic
(details below).
In total, 4381 (response rate 87.4%) participants underwent
complete (ophthalmic and general) examination at baseline.
Among those aged ‡50 years at baseline, the prevalence of
blindness was 1.6% (95%CI [confidence interval]: 1.2–2.1%),
and prevalence of VI was 13.6% (95%CI: 11.8–16.0%).13
Follow-up
Follow-up was conducted from January 2013 to March 2014.
Retracing at Follow-up: Advance Team. One week
before the follow-up examination clinic was planned for a given
cluster, a field officer studied the maps of the village including
Global Positioning System (GPS) coordinates recorded at
baseline and made phone contact with the village chief or
guide to arrange the visit. At the planning visit, a list of study
participants was given to the chief, and a local village guide was
recruited to assist location of the study participants. At this visit,
the examination site was established. Two days prior to the
clinic, the field officer reminded chiefs of the visit by phone and
notified them and the guide of the advance team’s arrival.
On the day prior to the examination clinic, the advance
team visited homes of baseline participants, confirmed their
identity using National Identity cards, and invited them to
attend the examination clinic the following day. All identified
participants were also asked to help locate baseline partici-
pants who had not been found.
Examination Clinic. The following procedures were
undertaken for all participants who attended the examination
clinic at both baseline and follow-up, and further details are
available elsewhere.11 Procedures undertaken but not included
in these analyses are not described in this report (e.g., visual
field assessment).
Registration. On the examination day, the advance team
confirmed the identity of participants against data from
baseline (age, date of birth, name, and identity cards). In cases
of uncertain identity, confirmation was made based on retinal
examination verified by comparison of retinal photos with
baseline photo (n ¼ 12).
Visual Acuity Assessment. Presenting VA was measured
using a back-illuminated modified logMAR reduced tumbling E
chart (Sussex Vision, Inc., Rustington, UK),14,15 which has
been used in previous population-based studies.16,17 Present-
ing VA was measured on all participants, that is, the patient’s
own correction was used if normally worn.
If the subject’s vision was too poor to read any letters on the
chart at 4 m, the subject was tested at 1 m, then as follows:
 Counting fingers (CF): ability to count fingers at 1-, 2-, or
3-m distance
 Hand motion (HM): ability to distinguish if a hand is
moving or not in front of the patient’s face
 Light perception (LP): ability to perceive any light
 No light perception (NLP): inability to see any light or
total blindness
Those who did not read 24 letters (VA < 20/40) at 4 m were
scheduled for correction and to undergo a repeat VA measure-
ment with the correction in place unless the vision was worse
than CF, in which case no correction was undertaken.
Anthropometry. A nurse performed and recorded measures
of participants: height (Leicester Height Measure; Chasmors
Ltd, London, UK); weight (Seca 761 Medical Class 4 Scales
mechanical ground scale; Williams Medical Supplies, London,
UK); waist and hip circumference (Chasmors Ltd WM02 Body
Tape measure); and three measures of blood pressure (Omron
Digital Automatic Blood Pressure Monitor Model HEM907;
Omron, Hoofddorp, The Netherlands), each 10 minutes apart.
In addition, at follow-up, bioimpedence (Tanita Segmental
Body Composition Monitor; Tanita, Amsterdam, The Nether-
lands) was performed.
At baseline, capillary blood was taken from all participants
for random blood glucose. Random blood glucose was also
taken at follow-up with the addition of glycosylated hemoglo-
bin (HbA1c) in all with a self-reported history of diabetes or
random blood glucose of ‡7.0 mM, and a further 10% of
nondiabetics (based on history and random blood glucose).
Interview. An interviewer performed a structured inter-
view in the participant’s preferred language covering demo-
graphic details; past medical and ocular history; known risk
factors (e.g., smoking and tobacco consumption and alcohol
intake); and socioeconomic status (e.g., job, housing condi-
tions, ownership of material goods and livestock).18
Definitions and Statistical Analyses
All participants who had complete examinations at baseline
who were not visually impaired or blind were considered ‘‘at
risk’’ for incident VI or blindness, respectively. Follow-up status
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at 6 years was categorized as Found and examined; Found and
not examined; Deceased; Moved away; or Unknown.
Statistical analysis was performed using STATA v13 (Stata
Corp, College Station, TX, USA). All analysis accounted for the
cluster survey design using Taylor linearized variance estima-
tion to calculate standard errors.
Preparation of Cohort for Analysis
Pearson v2 tests corrected for the survey design were used to
calculate P values in order to assess differences between
participants seen and those lost to follow-up (LTFU), and
between those known to have died and with unknown
outcome status. P < 0.1 was considered to represent a
statistically significant difference.
Those who were deceased were then excluded. Those
followed up but without complete records for all covariates at
baseline were also excluded.
An inverse probability weighting (IPW) model19 was
developed to allow estimation of cumulative incidence while
accounting for those LTFU. Multivariable logistic regression
was used to identify independent baseline covariates associat-
ed with LTFU. Covariates for which there was evidence of
univariable association with the outcome (P < 0.1) were kept
in a multivariable model. From this final model, the probability
of being followed was estimated, based on the presence or
absence of each of these baseline covariates. The inverse of
this probability formed the weighting to be applied in order to
account for those LTFU.
The final step was to remove those individuals LTFU from
the cohort, so that all subsequent analysis would be performed
on only those with complete outcome records, with IPW
applied to account for those LTFU. A sensitivity analysis for this
approach involved a complete records analysis (i.e., including
only those people who had complete records for outcome and
all variables in the analysis).
Estimation of Absolute and Relative Effects. The 6-year
cumulative incidence of each outcome was calculated by
dividing the number of events identified at 6-year follow-up by
the number of people at risk at the beginning of follow-up; 95%
confidence intervals were estimated assuming a Poisson
distribution of events. This analysis was done for the
population overall, and stratified by key covariates.
Age-adjusted risk ratios of the outcomes (VI and blindness,
respectively) were estimated for each covariate using a Poisson
regression model with robust error variance to allow for the
clustered design and including IPW. For multivariable analysis,
an initial model was fitted that included those variables
associated with outcome in age-adjusted analysis (Wald P value
< 0.05). A backward stepwise approach was applied to obtain a
final multivariable model, removing variables with P > 0.05.
Definitions. Visual acuity: WHO definitions of VI and
blindness were used throughout.20 Monocular VI was defined
as VA < 6/18 (20/60) in either eye. Visual impairment was
defined as a VA of <6/18 in the better eye. Monocular
blindness was defined as a VA of <3/60 (20/400) in either eye.
A person was considered to be blind if the VA in the better eye
was <3/60. The definition of VI also includes those who were
blind. An estimate of incident monocular and bilateral
blindness using the US definition was also calculated. The US
definition of monocular blindness is a Snellen acuity of 6/60
in either eye and 6/60 in the better eye for person
blindness.13
Diabetes: Diabetes was defined as self-reported in the
history, or random glucose ‡ 11.0 mM, or (3) HbA1c ‡ 7.0.
Socioeconomic status: A socioeconomic status (SES) score
was developed based on information collected on job, housing
conditions, and ownership of material goods and livestock,
based on previous work in the same population.18
Extrapolation of Data. Estimates of annual cumulative
incidence were extrapolated to estimate the number of adults
over the age of 50 with incident VI or blindness in Kenya each
year. This was calculated by taking the 2015 population
estimate from Kenya (Census Bureau of Kenya; Supplementary
Table S2) by age category and sex and multiplying this by the
age- and sex-specific estimates of annual cumulative incidence.
RESULTS
At baseline 4381 participants were examined (Fig.). Of these,
2645 (60%) were reidentified at the 6-year follow-up. The
reasons for non–follow-up were migration (n ¼ 321, 7%),
deceased (n ¼ 407, 10%), and unknown (n ¼ 1008, 23%). Of
the baseline participants, 2170 (50%) were reexamined. The
large number of unknowns is thought to be due to mass
displacement during the postelection violence in Kenya in
2007–2008.21 Of the 2170 participants followed up, 2164
(99.7%) had complete data. Those with complete data available
FIGURE. Flowchart of participants and nonparticipants.
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were used in the model for missing data and adjustment of
estimates. The mean follow-up time of all participants was 5.6
years (SD 0.6) and the median was 5.5 years (inter quartile
range, 5.0–6.1), expressed as a ‘‘6-year cumulative incidence’’
from here on. The Supplementary Figure includes the visual
status of participants at both time points in the cohort study.
Table 1 provides the baseline characteristics of partici-
pants who were reexamined at follow-up and those who were
LTFU. In comparison to participants, there was strong
evidence that those who had died during follow-up were
older, were more likely to be male, and had lower education
and SES. Compared with participants seen, those LTFU were
less likely to be Kikuyu or Kalenjin speakers, had lower levels
of education, were more likely to be from urban areas, and
had higher SES.
In those followed up, the prevalence of VI was higher at
follow-up (23%) than at baseline (13%), suggesting an overall
shift toward VI in this aging cohort (Table 2). Of the 45 blind at
follow-up, the majority were incident cases (n ¼ 29, 64%).
Eight of 24 blind persons at baseline were no longer blind at
follow-up, having received treatment in the interim period;
however, only 2 had achieved normal vision (Table 2).
Incidence of Blindness and Visual Impairment
Of the 2164 participants with complete follow-up data, 24
were blind at baseline and were therefore excluded from the
group considered at risk of becoming blind. We analyzed 2140
subjects at risk for incident blindness, of whom 29 participants
(1.36%, 95%CI: 0.9–1.9%) were blind at the follow-up visit
(Table 3). All subsequent results presented here have been
calculated based on the at-risk population and take account of
clustering, and also account for missing data via IPW, unless
otherwise stated.
The cumulative incidence, in participants aged 50 years and
over, of WHO-defined bilateral and unilateral VI was 119.4/
1000 (95%CI 103.1–137.9) and 228.0/1000 (95%CI 206.0–
251.6), respectively (Table 3). The cumulative incidence of
WHO-defined bilateral and unilateral blindness was 15.1/1000
(95%CI 10.4–21.7) and 54.6/1000 (95%CI 43.7–68.0), respec-
tively. Unweighted estimates using only those participants with
complete records of incidence were similar: WHO-defined
(Supplementary Table S3) bilateral and unilateral VI was 118.0/
1000 (95%CI 102.0–136.2) and 226.6/1000 (95%CI 204.8–
250.0), respectively (Supplementary Table S1), with estimates
TABLE 1. Baseline Characteristics in Nonblind Participants of the Nakuru Eye Disease Cohort Study: Participants and Nonparticipants (n¼ 4310)
Baseline Characteristics
Missing
Values
Participants Nonparticipants or Not Included in Analysis
Followed Up,
n ¼ 2140, 49.7%
Not Followed Up Alive/
Unknown/DM Status Missing,
n ¼ 1782, 41.3% P Value*
Deceased,
n ¼ 388, 9.0% P Value†
Age, y, mean (SD) 0 62.5 (9.3) 62.3 (10.1) 0.743 70.8 (12.4) <0.001
Sex, n (%)
Female 0 1011 (47.2) 821 (46.1) 0.521 223 (57.5) <0.001
Male 1129 (52.8) 961 (53.9) 165 (42.5)
Vision status impaired,
presenting <6/12
better eye, n (%)
Normal 0 1983 (92.7) 1646 (92.4) 0.734 307 (79.1) <0.001
Impaired 157 (7.3) 136 (7.6) 81 (20.9)
Tribe, n (%)
Kikuyu 0 1378 (64.4) 1064 (59.7) <0.001 272 (70.1) 0.059
Kalenjin 530 (24.8) 365 (20.5) 84 (21.6)
Other 232 (10.8) 353 (19.8) 32 (8.2)
Education, n (%)
None 11 192 (9.0) 203 (11.4) 0.030 25 (6.5) 0.001
Primary 668 (31.2) 568 (32.0) 163 (42.1)
Secondary 1061 (49.6) 793 (44.7) 170 (43.9)
Higher 217 (10.1) 210 (11.8) 29 (7.5)
Residence, n (%)
Rural 0 1612 (75.3) 995 (55.8) <0.001 288 (74.2) 0.696
Urban 528 (24.7) 787 (44.2) 100 (25.8)
SES quartile, n (%)
Lower 31 499 (23.4) 432 (24.5) 0.008 125 (32.3) 0.004
Middle lower 587 (27.6) 394 (22.3) 91 (23.5)
Middle upper 550 (25.8) 429 (24.3) 94 (24.3)
Upper 493 (23.2) 508 (28.8) 77 (19.9)
4381 individuals had a baseline measure of visual acuity. Of these, 71 were classified as blind, so the 4310 individuals who had a visual acuity
measure and were nonblind contributed to this table. DM, diabetes mellitus.
* P value for association between the baseline characteristic and the odds of having a valid VI observation at follow-up, among all participants
identified as nonblind at baseline and not known to be deceased at follow-up.
† P value for association between the baseline characteristic and the odds of dying during the follow-up period, among all participants identified
as nonblind at baseline and either followed up or known to be deceased at follow-up (i.e., excluding the group who were not followed up).
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of blindness being slightly lower at 13.6/1000 (95%CI 9.5–
19.4).
The cumulative incidence using the US definitions of
blindness was estimated to enable comparison with other
cohorts, and was higher than for WHO estimates (Table 3). All
further analyses are based on WHO definitions.
There was strong evidence of an increase in 6-year
cumulative incidence of VI and blindness by age (Table 4).
Overall differences in sex across all age categories were not
evident; however, a significant difference was found between
male and females aged ‡80 years for cumulative incidence of
both VI and blindness.
Extrapolations based on recent census data were used to
calculate the number of individuals aged ‡50, by age and sex,
estimated to become visually impaired or blind in Kenya each
year (Table 5, Supplementary Table S4). There are an estimated
21 new cases of VI in people aged ‡50 years per 1000 total
population per year, of whom 3 (2.7) are blind. Therefore in
Kenya we estimate that there are 92,000 new cases of VI per
year in people aged ‡50 years, of whom 11,600 are blind, out
of a total population of approximately 4.3 million people aged
‡50 (Supplementary Table S5).
Data from other similar populations indicate that 85% of
blindness prevalence is among those aged ‡50 years.22
Assuming that the relative incidence of blindness in the under-
and over-50s is comparable to the prevalence (i.e., 85% of
incidence is also in the over-50s), extrapolating to all ages, we
estimate that there are 1.66 new cases of blindness per 1000
per year in all ages in Kenya, approximately 76,000 new cases
annually out of a total population of 46 million.
Multivariable analysis for incident bilateral blindness and VI,
respectively, showed only diabetes and increasing age to be
associated (Table 6). However, low numbers of incident cases
of blindness and wide confidence intervals make drawing
conclusions limited for this group. There was no evidence of
an association with all other risk factors.
DISCUSSION
There are few longitudinal population-based studies describing
the incidence of blindness and VI worldwide, and data from
sub-Saharan Africa are particularly sparse (Table 7). The data
build on our previously reported population-based estimates of
prevalence in the same population.13
We found that the annual incidence of blindness in those
aged 50 years and over was 2.2 per 1000 people per year using
the WHO definition (VA < 20/400 Snellen in the better-seeing
eye) and 4.3 per 1000 for the US definition (VA  20/200 in the
better-seeing eye). The annual incidence of VI (VA < 6/18
Snellen in the better-seeing eye) was 20.9 per 1000 people per
year. These estimates are substantially higher annual incidence
rates of VI and blindness when compared with other cohort
studies (Table 7). It should be noted that comparable studies
had varying follow-up periods and thus comparison is made
based on annual incidence.
As expected, the incidence of VI and blindness increased
significantly with age, as seen in all previous comparable
cohort studies. This reflects age-related changes to the
crystalline lens and age-related retinal and nerve diseases.
TABLE 3. Six-Year Adjusted Cumulative Incidence of Unilateral and Bilateral Visual Impairment by WHO and US Criteria Among the Nakuru Eye
Disease Cohort Study Participants
Incidence of
WHO Criteria US Criteria
Incident Cases/
At Risk Cases
Cumulative
Incidence,
n per 1000
of Population
(95% CI)
Cumulative Incidence
per Million of Population,
n per 1 Million
of Population
(95% CI)
Incident Cases/
At Risk Cases
Cumulative
Incidence,
n per 1000
of Population
(95% CI)
Bilateral blindness 29/2140 15.1 (10.4–21.7) 15,100 (10,400–21,700) 53/2122 25.9 (19.4–34.4)
Bilateral visual impairment 234/1983 119.4 (103.1–137.9) 119,400 (103,100–137,900) – –
Unilateral blindness 111/1984 54.6 (43.7–68.0) 54,600 (43,700–68,000) 154/1937 79.9 (68.2–93.4)
Unilateral visual impairment 390/1721 228.0 (206.0–251.6) 228,000 (206,000–251,600) – –
WHO definition: blind, Snellen acuity < 3/60 (<20/400); visually impaired, Snellen acuity < 6/12 (<20/40). US definition: blind, Snellen acuity
 6/60. Cumulative incidence adjusted for missing data. 2164 individuals had VA measurements at baseline and follow-up, but 24 of these had WHO
bilateral blindness at baseline, hence 2164 24¼ 2140 at risk; 181 had WHO bilateral visual impairment at baseline, hence 2164 181¼ 1983 at
risk; 180 had WHO unilateral blindness at baseline, hence 2164 180¼ 1984 at risk; 443 had WHO unilateral visual impairment at baseline, hence
2164 443¼ 1721 at risk; 42 had US-defined bilateral blindness, hence 2164 42¼ 2122 at risk; 227 had US-defined unilateral blindness, hence
2164  227 ¼ 1937 at risk.
TABLE 2. Change in Presenting Visual Acuity Category From Baseline to Follow-Up in Cohort With Visual Acuity Data From Both Time Points (n¼
2164)
Baseline
Follow-Up
‡6/12 <6/12–6/18 <6/18–6/60 <6/60–3/60 <3/60 Total
‡6/12 1474 227 166 4 10 1881, 86.9%
<6/12–6/18 18 30 51 1 2 102, 4.7%
<6/18–6/60 15 22 82 16 15 150, 6.9%
<6/60–3/60 0 0 5 0 2 7, 0.3%
<3/60 2 1 4 1 16 24, 1.1%
Total 1509, 69.7% 280, 12.9% 308, 14.2% 22, 1.0% 45, 2.0% 2164, 100%
2164 individuals had both a baseline measure of visual acuity and a follow-up measure of visual acuity. All are included in this table. Visual acuity
categories are presenting visual acuity in the better of eye of the individual.
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The disease-specific incidence rates will be presented and
discussed in separate reports.
One previous study from Uganda assessed the incidence of
VI and blindness in an African population from a population-
based cohort that was established to assess the dynamics of
human immunodeficiency virus (HIV) infection through annual
censuses and serologic surveys,29 and incorporated an
assessment of vision at two time points. The sample was a
general population cohort and not designed specifically for eye
disease, measuring only VA (modified Snellen chart).30 Only
one case of incident bilateral blindness was reported and 21
cases of incident VI in the study sample (aged 13 and above),
providing an age-standardized incidence rate of bilateral VI of
13.2 persons per 1000 persons per year (in a different age
group from that presented from this population).31 In
comparison, this study estimated an incidence of VI at 20.9
persons per 1000 per year.
There are data from comparable population-based studies of
eye disease worldwide (Table 7). There are some variations in
the age group considered for inclusion, although the majority
sampled those 40 or 50 years and above. Most studies
presented incident data using the WHO and US definitions of
VI or blindness, but some included only one definition, limiting
comparability across studies. The incidence of bilateral VI in
the Nakuru Eye Disease Cohort Study was found to be higher
than anywhere else in the world. The annual incidence rate
(persons per 1000 per year) for the majority of studies (eight)
was between 0.2 and 0.9 (US classifications) and 0.1 and 0.5
(WHO classifications).8–10,23,25–28 Only two studies were
higher, at 1.1 (US) and 2.1 (WHO) for the Barbados Eye
Study24 and 1.2 (US) and 2.4 (WHO) for the Nakuru Eye
Disease Cohort Study, respectively.
The high incidence in this study most likely reflects a
combination of low access to ophthalmic services and health
services in general32; there was only one ophthalmologist in the
region of the study for a population of approximately 1.6 million
people. Other explanations include environmental risk factors
including geography, diet, ethnic origin, and ultraviolet light
exposure. Other barriers to eye care provision in the region
include a low awareness of treatable sight loss, available services
that are unaffordable and far away, and fear of treatment.
The data in this study indicated that of 29 new cases of
blindness at follow-up, 12 had VA of 6/18 or better, and 17
were worse than 6/18 (see Table 2). Of the 24 who were blind
at baseline, 16 were still blind at follow-up. Further analysis
will disaggregate incident VI and blindness by cause, enabling
TABLE 5. Extrapolated Number of Adults per Year, Aged 50 Years and Over, in Kenya With New Visual Impairment and Blindness Based on
Weighted Incidence Data and Estimates of the Population in Kenya by Age Group in 2015
Age Group,
Years
Male Female Overall
Extrapolated
Number
Lower,
95%CI
Upper,
95%CI
Extrapolated
Number
Lower,
95%CI
Upper,
95%CI
Extrapolated
Number
Lower,
95%CI
Upper,
95%CI
Visual impairment
50–59 11,480 7,620 17,080 10,130 6,910 14,740 21,340 16,090 28,160
60–69 9,710 6,830 13,600 13,030 9,490 17,660 22,670 17,760 28,710
70–79 7,700 5,380 10,650 13,670 10,260 17,680 20,720 16,920 25,040
80þ 2,200 1,310 3,340 4,470 2,920 6,200 6,490 4,830 8,350
All age groups 34,550 27,580 43,000 42,230 35,430 50,120 76,740 66,240 88,650
Blindness, <3/60 better eye
50–59 400 50 2,890 – – – 350 50 2,550
60–69 1,350 560 3,190 1,160 350 3,810 2,560 1,250 5,200
70–79 1,200 430 3,280 1,340 530 3,330 2,580 1,280 5,120
80þ 680 200 2,070 2,190 1,160 3,900 2,680 1,520 4,580
All age groups 4,870 2,690 8,780 5,740 3,550 9,240 10610 7,340 15,300
TABLE 4. Age- and Sex-Specific 6-Year Adjusted Cumulative Incidence of Visual Impairment and Blindness by WHO Definition Among the Nakuru
Eye Disease Cohort Study Participants
Age Group,
Years
Male Female Overall
n, Cases/
At Risk
Risk per
1000/6 Years
(95%CI) n
Risk per
1000/6 Years
(95%CI) n
Risk per
1000/6 Years
(95%CI)
Visual impairment, <6/18 better eye
50–59 27/402 66.5 (44.2–99.0) 30/556 53.3 (36.3–77.5) 57/958 58.8 (44.4–77.6)
60–69 35/328 110.4 (77.6–154.7) 37/314 119.8 (87.2–162.3) 72/642 115.1 (90.2–145.8)
70–79 34/156 218.4 (152.8–302.3) 39/137 283.8 (213.1–367.1) 73/293 249.9 (204.1–302.0)
80þ 13/43 308.5 (183.6–469.5) 19/47 411.4 (268.9–570.5) 32/90 363.2 (270.6–467.3)
All age groups 109/929 118.6 (94.6–147.5) 125/1054 120.1 (100.8–142.6) 234/1983 119.4 (103.1–137.9)
Blindness, <3/60 better eye
50–59 1/407 2.3 (0.3–16.5) 0/568 – 1/975 0.9 (0.1–6.9)
60–69 5/353 14.4 (6.0–34.3) 3/337 9.8 (3.0–32.3) 8/690 12.1 (5.9–24.7)
70–79 4/183 28.6 (10.1–77.8) 4/157 24.0 (9.4–59.7) 8/340 26.4 (13.1–52.4)
80þ 3/68 58.4 (17.4–178.7) 9/67 129.7 (68.6–231.6) 12/135 94.6 (53.7–161.5)
All age groups 13/1011 15.2 (8.4–27.4) 16/1129 15.0 (9.3–24.1) 29/2140 15.1 (10.4–21.7)
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further data to support planning (e.g., estimation of need for
cataract surgery).
Strengths of the study include the following characteristics:
a representative population-based sample in an area of ethnic,
socioeconomic, and educational diversity; a large sample size;
comprehensive assessment of risk factors; high-quality assess-
ment of vision; and utilization of the same tools at baseline and
follow-up. The methodology used to assess ophthalmic disease
was consistent with studies performed in well-developed
health systems in high-income countries such as the United
States23 and Australia,8 with use of the latest available
equipment,11 thus making the data highly comparable to those
in other population-based cohort studies of eye disease.
The major limitation of this study was low participation rate
(50%) at 6 years; however, having the baseline characteristics
of nonparticipants is a strength that enabled weighting to
ensure better estimates of cumulative incidence. This loss to
follow-up may have led to an under- or overestimation of
incident VI and blindness, depending on the general charac-
teristics of the nonrespondents. The predominant risk factor
for incident VI or blindness was age; and given that this was
closely matched between participants and nonparticipants
(62.7 years [SD 9.4] and 62.5 years [SD 10.4], respectively), the
estimates are likely to be an acceptable reflection. This
assessment is further supported in that minimal changes were
apparent after adjusting estimates for missing data (Supple-
mentary Table S1).
Reasons for the low participation included ethnic violence
and displacement of large numbers of people in the study
sample area. Postelection violence in 2007 and 2008 led to up
to 600,000 people being internally displaced and 1300
fatalities.21 In a number of study clusters, entire ethnic groups
present at baseline were no longer available or traceable.
Great efforts were made to locate individuals. Further
limitations include restricting the inclusion criteria at baseline
to those 50 years and above, thereby reducing the generaliz-
ability of our results to the entire population. This is, however,
comparable to the majority of population-based studies of eye
disease that restrict inclusion to 40 or 50 years and above
(Table 7). Furthermore, the majority of prevalent and incident
vision loss is in this age group, making the sample size
feasible.22 The definition of blindness and VI in this study did
not include peripheral vision loss and was based solely on
presenting central logMAR VA. This potentially underestimates
the incident VI and blindness (particularly from glaucoma)
when compared to studies that include these criteria.
Our results suggest that there are 86,000 new cases of VI in
people aged ‡50 years per year in Kenya, of whom 8100 are
blind. Recent estimates suggest that there are 86 ophthalmol-
ogists in Kenya33 for a population of approximately 45 million,
with the majority (50%) being based in the capital city of
Nairobi. This leaves 92% of the population (approximately 40
million people) being served by 43 ophthalmologists. Overall,
Kenya is better resourced than many other African countries in
terms of human resources, despite still being well below
recommended targets.34 Continued effort to strengthen the
eye health system is necessary to support the growing unmet
need of this aging and growing population.
In conclusion, the incidence of VI and blindness in this
adult Kenyan population was considerably higher than in
comparable studies worldwide. Further analyses on the causes
of incident blindness will help in setting priorities for
preventing avoidable blindness in this population.
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